SequelSEC

SpyGlass Pharma, Inc. SGP

Surgical & Medical Instruments & Apparatus · CIK 0001778922 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$21.97M
Fiscal year ended 2026-06-30
Free cash flow
-$16.77M
Fiscal year ended 2026-06-30

SpyGlass Pharma, Inc. (SGP) reported net income of -$19.86M for the fiscal year ended 2026-06-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from SpyGlass Pharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

SpyGlass Pharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$21.97MUnavailable-$24.73M-$9.30MUnavailableUnavailable
Net income-$19.86MUnavailable-$22.37M-$8.68MUnavailableUnavailable
Research & development$10.94MUnavailable$15.80M$7.33MUnavailableUnavailable
Weighted-average diluted sharesshares 33.44MUnavailableUnavailableshares 2.28MUnavailableUnavailable
Pretax income-$19.86MUnavailable-$22.37M-$8.68MUnavailableUnavailable
Income tax expense$0Unavailable$0$0UnavailableUnavailable
Diluted EPS$-0.59UnavailableUnavailable$-3.81UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$11.02MUnavailable$8.93M$1.96MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

SpyGlass Pharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Cash & equivalents$223.14MUnavailable$96.36MUnavailableUnavailable$16.27M
Total assets$243.43MUnavailable$115.87MUnavailableUnavailable$23.32M
Current assets$236.46MUnavailable$108.77MUnavailableUnavailable$17.41M
Total liabilities$11.07MUnavailable$10.17MUnavailableUnavailable$11.25M
Current liabilities$9.44MUnavailable$8.58MUnavailableUnavailable$7.79M
Total equity incl. NCI$232.36MUnavailable-$98.84M-$78.38MUnavailable-$60.47M
Temporary (mezzanine) equity$0Unavailable$204.54M$204.54MUnavailable$72.55M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.16MUnavailable$2.70MUnavailableUnavailable$1.98M

Cash flow

SpyGlass Pharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Operating cash flow-$14.84MUnavailable-$18.18M-$6.32MUnavailableUnavailable
Capital expenditures$1.93MUnavailable$573.00K$52.00KUnavailableUnavailable
Investing cash flow-$933.00KUnavailable-$11.58M-$52.00KUnavailableUnavailable
Financing cash flow$13.00KUnavailable-$1.12M$75.61MUnavailableUnavailable
Net change in cash-$15.76MUnavailable-$30.88M$69.24MUnavailableUnavailable
Stock-based compensation$2.08MUnavailable$1.85M$587.00KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0UnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

SpyGlass Pharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Free cash flow-$16.77MUnavailable-$18.75M-$6.38MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio25.06xUnavailable12.67xUnavailableUnavailable2.23x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SGP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-26View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.